Recent research from Washington University School of Medicine in St. Louis has uncovered how the brain and immune system communicate to maintain a crucial balance between defending against infections and preserving healthy tissue. The study, published on October 30 in *Nature*, identifies immune-stimulating protein fragments known as guardian peptides, produced by the brain and spinal cord, that play a vital role in regulating this interaction. 

Jonathan Kipnis, PhD, the Alan A. and Edith L. Wolff Distinguished Professor of Pathology & Immunology, emphasized the significance of these findings: “We have discovered guardian brain peptides that actively engage with the immune system, potentially preventing harmful immune responses.” This research holds promise for enhancing treatments for various neuroinflammatory diseases, including multiple sclerosis (MS) and Alzheimer's disease. 

Immune surveillance relies on T cells that respond to threats by recognizing tiny protein fragments presented by specialized immune cells. The study revealed that guardian peptides are displayed at the brain’s borders, attracting regulatory T cells that help suppress abnormal immune reactions. Min Woo Kim, a graduate student and researcher in Kipnis’s lab, investigated these immune cells in healthy mice and found that a key protein involved in myelin sheath integrity, which is often damaged in MS, was presented abundantly. However, in mice with MS, these proteins were significantly reduced. 

To address this, the researchers injected vesicles containing the missing brain-derived peptides into the cerebrospinal fluid of MS-afflicted mice. This treatment successfully activated and expanded a subset of suppressor T cells, leading to improved motor function and slowed disease progression compared to control mice. 

Kim noted, “We have identified a novel mechanism where the brain engages with the immune system to present a healthy representation of itself. In the case of MS, this representation is altered. We believe that other neuroinflammatory and neurodegenerative diseases may also exhibit distinct protein signatures that could serve as diagnostic markers.” 

The study also involved contributions from other WashU Medicine researchers, including Cheryl Lichti, Clair Crewe, and Maxim N. Artyomov, alongside the late Emil R. Unanue, who made significant contributions to the understanding of T cell interactions. 

This groundbreaking research provides insights into how the central nervous system manages immune privilege and suggests new avenues for therapeutic development to mitigate inappropriate immune responses in neuroinflammatory diseases.